Delighted to be working with Jenny Barnett and her team at new CNS digital biomarker company Monument Therapeutics. A spin-out from Cambridge Cognition, the initial focus will be on schizophrenia and post-operative cognitive decline.
Delighted to be working with Jenny Barnett and her team at new CNS digital biomarker company Monument Therapeutics. A spin-out from Cambridge Cognition, the initial focus will be on schizophrenia and post-operative cognitive decline.